Hypophosphatemia Clinical Trial
Official title:
Effects of Treatments for Anemia and Iron Deficiency on the Electrolyte Balance in Lung Transplant Recipients: A Special Focus on Hypophosphatemia
Verified date | October 2023 |
Source | University of Zurich |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The aim of this study is to generate evidence regarding hypophosphatemia after iron infusion in lung transplant recipients in context of anemia and/or iron deficiency.
Status | Active, not recruiting |
Enrollment | 250 |
Est. completion date | March 31, 2027 |
Est. primary completion date | December 31, 2026 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - lung transplant recipient - treated at the University Hospital Zurich between 2015 until 2022 Exclusion Criteria: - Denied general consent |
Country | Name | City | State |
---|---|---|---|
Switzerland | University Hospital Zurich | Zurich |
Lead Sponsor | Collaborator |
---|---|
University of Zurich |
Switzerland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of serum phosphate level | Change of serum phosphate level before and after iron infusion | Baseline and up to 90 days after iron infusion | |
Secondary | Change of urin phosphate level | Change of urin phosphate level before and after iron infusion | Baseline and up to 90 days after iron infusion | |
Secondary | Change of hemoglobin | Change of hemoglobin level before and after iron infusion | Baseline and up to 90 days after iron infusion | |
Secondary | Change of mean corpuscular volume (MCV) | Changes of serum MCV level before and after iron infusion | Baseline and up to 90 days after iron infusion | |
Secondary | Change of mean corpuscular hemoglobin (MCH) | Change of serum MCH level before and after iron infusion | Baseline and up to 90 days after iron infusion | |
Secondary | Change of serum magnesium | Change of serum magnesium level before and after iron infusion | Baseline and up to 90 days after iron infusion | |
Secondary | Change of serum and urin calcium | Change of serum and urin calcium level before and after iron infusion | Baseline and up to 90 days after iron infusion | |
Secondary | Change of serum albumin | Change of serum albumin level before and after iron infusion | Baseline and up to 90 days after iron infusion | |
Secondary | Complications after iron infusion | Number of patients with complications due to hypophosphatemia after iron infusion (Hospitalization, hypoxia, fracture due to hypophosphatemia) | 2015-2022 | |
Secondary | Predictors | Analysis of possible predictors for the decrease of serum phosphate levels after iron infusion | baseline and up to 90 days after iron infusion | |
Secondary | Therapeutic management | Descriptive analysis of therapeutic management of hypophosphatemia after iron infusion | 2015 to 2022 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04519762 -
Levels of 'Hypophosphatemia Affect Outcome of Septic Patients in ICU
|
Phase 4 | |
Enrolling by invitation |
NCT04502784 -
Investigation of Hypophosphataemia Following Intravenous Iron
|
||
Completed |
NCT03529058 -
Hypophosphatemia as a Predictive Marker of Mortality During Sepsis in ICU
|
||
Terminated |
NCT01011114 -
Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant
|
N/A | |
Completed |
NCT05098249 -
Ferric Carboxymaltose With or Without Phosphate Substitution for the Treatment of Iron Deficiency or Iron Deficiency Anemia
|
Phase 4 | |
Not yet recruiting |
NCT06350955 -
IV Iron-induced Hypophosphatemia After RYGB
|
Phase 4 | |
Completed |
NCT00688077 -
FGF-23 Suppressibility by Calcitonin
|
N/A | |
Recruiting |
NCT04814641 -
Hypophosphatemia and Bronchiolitis
|
||
Recruiting |
NCT01660308 -
Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced Osteomalacia
|
N/A | |
Active, not recruiting |
NCT03976440 -
Simplified Regional Citrate Anticoagulation Protocols for CVVH, CVVHDF and SLED: a Pilot Study
|
||
Recruiting |
NCT05909722 -
Validation of the GIDS and Description of Phosphate Disorders
|
||
Completed |
NCT03581591 -
Open Label Trial Assessing Safety and Efficacy of Burosumab (KRN23), in a Patient With ENS and Hypophosphatemic Rickets
|
Phase 3 | |
Completed |
NCT03740802 -
Hypophosphatemia as a Predictor in Surgical Resuscitation Sepsis
|
||
Suspended |
NCT03771105 -
The Impact of Phosphate Metabolism on Healthy Aging
|
Early Phase 1 | |
Completed |
NCT03489993 -
FGF23 and Angiotensin-(1-7) in Hypophosphatemia (GAP)
|
||
Completed |
NCT00975000 -
Treatment of Autonomous Hyperparathyroidism in Post Renal Transplant Recipients
|
Phase 3 | |
Withdrawn |
NCT02837523 -
Biomarker for Cystinosis Disease: BioCystinosis (BioCystinosis)
|
||
Not yet recruiting |
NCT06344546 -
Metabolic Pathway Analysis in Intensive Care Unit Patients With Refeeding Syndrome
|